keyword
MENU ▼
Read by QxMD icon Read
search

Influenza hemagglutinin

keyword
https://www.readbyqxmd.com/read/28921955/characterization-of-site-specific-glycosylation-in-influenza-a-virus-hemagglutinin-produced-by-spodoptera-frugiperda-insect-cell-line
#1
Yanjun Liu, Shiaw-Lin Wu, Kerry Routenberg Love, William S Hancock
Influenza hemagglutinin is a surface glycoprotein related to virus invasion and host immune system response. Understanding site specific glycosylation of hemagglutinin will increase our knowledge about virus evolution and can improve the design and quality of vaccines. In our study, we used glycoproteomic analysis based on multienzyme digestion followed by LC tandem MS analysis to determine the glycosylation of Influenza hemagglutinin (H1/A/California/04/2009) using the following steps: PNGaseF treatment combined with trypsin or pepsin digestion were used to determine the glycosites and glycan occupancy...
September 18, 2017: Analytical Chemistry
https://www.readbyqxmd.com/read/28917539/hemagglutinin-specific-cd4-t-cell-responses-following-2009-ph1n1-inactivated-split-vaccine-inoculation-in-humans
#2
Shuguang Tan, Shihong Zhang, Bin Wu, Yingze Zhao, Wei Zhang, Min Han, Ying Wu, Guoli Shi, Yingxia Liu, Jinghua Yan, Guizhen Wu, Hua Wang, George F Gao, Fengcai Zhu, William J Liu
Influenza A virus remains a major threat to public health, and the inactivated split-virus vaccine is the most prevalent vaccine used worldwide. However, our knowledge about cellular immune responses to the inactivated influenza virus vaccine and its correlation with humoral responses are yet limited, which has restricted our understanding of the vaccine's protective mechanisms. Herein, in two clinical trials, T-cell responses specific for both previously identified human leucocyte antigen (HLA)-I-restricted epitopes from influenza virus and hemagglutinin (HA) protein were longitudinally investigated before, during, and after a two-dose vaccination with the inactivated 2009 pandemic H1N1 (2009-pH1N1) vaccine...
September 13, 2017: Vaccine
https://www.readbyqxmd.com/read/28917132/a-novel-real-time-rt-pcr-assay-for-influenza-c-tested-in-peruvian-children
#3
Leigh M Howard, Monika Johnson, Ana I Gil, Andrew Pekosz, Marie R Griffin, Kathryn M Edwards, Claudio F Lanata, Carlos G Grijalva, John V Williams
BACKGROUND: Influenza C virus (ICV) is associated with acute respiratory illness. Yet ICV remains under recognized, with most previous studies using only culture to identify cases. OBJECTIVES: To develop a sensitive and specific real-time RT-PCR assay for ICV that allows for rapid and accurate detection in a clinical or research setting. STUDY DESIGN: Multiple ICV sequences obtained from GenBank were analyzed, including 141 hemagglutinin-esterase (HE), 106 matrix (M), and 97 nucleoprotein (NP) sequences...
September 1, 2017: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
https://www.readbyqxmd.com/read/28915027/structure-and-dynamics-of-membrane-proteins-and-membrane-associated-proteins-with-native-bicelles-from-eukaryotic-tissues
#4
Sean T Smrt, Adrian W Draney, Indira Singaram, Justin L Lorieau
In vitro studies of protein structure, function and dynamics typically preclude the complex range of molecular interactions found in living tissues. In vivo studies elucidate these complex relationships, yet they are typically incompatible with the extensive and controlled biophysical experiments available in vitro. We present an alternative approach by extracting membranes from eukaryotic tissues to produce native bicelles to capture the rich and complex molecular environment of in vivo studies while retaining the advantages of in vitro experiments...
September 15, 2017: Biochemistry
https://www.readbyqxmd.com/read/28912784/comparison-of-the-protective-efficacy-of-neutralizing-epitopes-of-2009-pandemic-h1n1-influenza-hemagglutinin
#5
Bo Peng, Na Peng, Yanan Zhang, Fenghua Zhang, Xuguang Li, Haiyan Chang, Fang Fang, Fuyan Wang, Fangguo Lu, Ze Chen
The 2009 H1N1 influenza (Pdm09) pandemic has been referred to as the first influenza pandemic of the twenty-first century. There is a marked difference in antigenicity between the pandemic H1N1 virus and past seasonal H1N1 viruses, which allowed the pandemic virus to spread rapidly in humans. Antibodies (Abs) against hemagglutinin (HA), especially neutralizing Abs against epitopes in the head of HA, play critical roles in defending the host against the virus. Some preexisting neutralizing Abs that recognize neutralizing epitopes of Pdm09 HA, thereby affording cross-protection, have been reported...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28912070/recombinant-influenza-h7-hemagglutinin-containing-cfllc-minidomain-in-the-transmembrane-domain-showed-enhanced-cross-protection-in-mice
#6
Yang Wang, Yun Zhang, Jialing Wu, Ying Lin, Zhihui Wu, Ying Wei, Xiaona Wei, Jianru Qin, Chunyi Xue, George Dacai Liu, Yongchang Cao
Since February 2013, H7N9 influenza virus, causing human infections with high mortality in China, has been a potential pandemic threat. The H7N9 viruses are found to diverge into distinct genotypes as other influenza viruses; thus a vaccine that can provide sufficient cross-protection against different genotypes of H7N9 viruses is urgently needed. Our previous studies demonstrated that the HA-based structural design approach by introducing a CFLLC minidomain into transmembrane domain (TM) of H1, H5 or H9 hemagglutinin (HA) proteins by replacing with H3 subtype HA TM could enhance their cross-protection...
September 11, 2017: Virus Research
https://www.readbyqxmd.com/read/28910866/an-aptamer-based-electrochemical-sensor-that-can-distinguish-influenza-virus-subtype-h1-from-h5
#7
Jin-Moo Lee, JunWon Kim, Ilhwan Ryu, Hye-Min Woo, Tae Gyun Lee, Woong Jung, Sanggyu Yim, Yong-Joo Jeong
The surface protein hemagglutinin (HA) mediates the attachment of influenza virus to host cells containing sialic acid and thus facilitate viral infection. Therefore, HA is considered as a good target for the development of diagnostic tools for influenza virus. Previously, we reported the isolation of single-stranded aptamers that can distinguish influenza subtype H1 from H5. In this study, we described a method for the selective electrical detection of H1 using the isolated aptamer as a molecular probe. After immobilization of the aptamer on Si wafer, enzyme-linked immunosorbent assay (ELISA) and field emission scanning electron microscope (FE-SEM) showed that the immobilized aptamer specifically bound to only the H1 subtype but not the H5 subtype...
September 15, 2017: Journal of Microbiology and Biotechnology
https://www.readbyqxmd.com/read/28910636/epitranscriptomic-enhancement-of-influenza-a-virus-gene-expression-and-replication
#8
David G Courtney, Edward M Kennedy, Rebekah E Dumm, Hal P Bogerd, Kevin Tsai, Nicholas S Heaton, Bryan R Cullen
Many viral RNAs are modified by methylation of the N(6) position of adenosine (m(6)A). m(6)A is thought to regulate RNA splicing, stability, translation, and secondary structure. Influenza A virus (IAV) expresses m(6)A-modified RNAs, but the effects of m(6)A on this segmented RNA virus remain unclear. We demonstrate that global inhibition of m(6)A addition inhibits IAV gene expression and replication. In contrast, overexpression of the cellular m(6)A "reader" protein YTHDF2 increases IAV gene expression and replication...
September 13, 2017: Cell Host & Microbe
https://www.readbyqxmd.com/read/28905402/affinity-capillary-electrophoresis-for-the-assessment-of-binding-affinity-of-carbohydrate-based-cholera-toxin-inhibitors
#9
Oier Aizpurua-Olaizola, Javier Sastre Torano, Aliaksei Pukin, Ou Fu, Geert Jan Boons, Gerhardus J de Jong, Roland J Pieters
Developing tools for the study of protein carbohydrate interactions is an important goal in glycobiology. Cholera toxin inhibition is an interesting target in this context, as its inhibition may help the fight against cholera. For the study of novel ligands an affinity capillary electrophoresis (ACE) method was optimised and applied. The method uses unlabeled cholera toxin B-subunit (CTB) and unlabeled carbohydrate ligands based on ganglioside GM1-oligosaccharides (GM1os). In an optimized method at pH 4, adsorption of the protein to the capillary walls was prevented by a polybrene-dextran sulfate-polybrene (PB-DS-PB) coating...
September 14, 2017: Electrophoresis
https://www.readbyqxmd.com/read/28904995/distribution-of-o-acetylated-sialic-acids-among-target-host-tissues-for-influenza-virus
#10
Brian R Wasik, Karen N Barnard, Robert J Ossiboff, Zahra Khedri, Kurtis H Feng, Hai Yu, Xi Chen, Daniel R Perez, Ajit Varki, Colin R Parrish
Sialic acids (Sias) are important glycans displayed on the cells and tissues of many different animals and are frequent targets for binding and modification by pathogens, including influenza viruses. Influenza virus hemagglutinins bind Sias during the infection of their normal hosts, while the encoded neuraminidases and/or esterases remove or modify the Sia to allow virion release or to prevent rebinding. Sias naturally occur in a variety of modified forms, and modified Sias can alter influenza virus host tropisms through their altered interactions with the viral glycoproteins...
September 2017: MSphere
https://www.readbyqxmd.com/read/28903071/highly-conserved-m2e-and-hemagglutinin-epitope-based-recombinant-proteins-induce-protection-against-influenza-virus-infection
#11
Yan Guo, Lei He, Nianping Song, Pei Li, Shihui Sun, Guangyu Zhao, Wanbo Tai, Shibo Jiang, Lanying Du, Yusen Zhou
Highly pathogenic influenza viruses continue to cause serious threat to public health due to their pandemic potential, calling for an urgent need to develop effective, safe, convenient, and universal vaccines against influenza virus infection. In this study, we constructed two recombinant protein vaccines, 2H5M2e-2H7M2e-H5FP-H7FP (hereinafter M2e-FP-1) and 2H5M2e-H5FP-2H7M2e-H7FP (hereinafter M2e-FP-2), by respectively linking highly conserved sequences of two molecules of ectodomain of M2 (M2e) and one molecule of fusion peptide (FP) epitope of hemagglutinin (HA) of H5N1 and H7N9 influenza viruses in different orders...
September 10, 2017: Microbes and Infection
https://www.readbyqxmd.com/read/28899494/intranasal-co-administration-of-1-8-cineole-with-influenza-vaccine-provide-cross-protection-against-influenza-virus-infection
#12
Yun Li, Yu-Ling Xu, Yan-Ni Lai, Shang-Hui Liao, Ni Liu, Pei-Ping Xu
BACKGROUND: Vaccination is the most efficient means for protection against influenza. However, the various vaccines have low efficacy to protect against pandemic strains because of antigenic drift and recombination of influenza virus. Adjuvant therapy is one of the attempts to improve influenza vaccine effective cross-protection against influenza virus infection. Our previous study confirmed that 1,8-cineole inhibits the NF-κB, reduces pro-inflammatory cytokines, and relieves the pathological changes of viral pneumonia in mice infected with influenza virus...
October 15, 2017: Phytomedicine: International Journal of Phytotherapy and Phytopharmacology
https://www.readbyqxmd.com/read/28895870/protection-of-commercial-turkeys-following-inactivated-or-recombinant-h5-vaccine-application-against-the-2015u-s-h5n2-clade-2-3-4-4-highly-pathogenic-avian-influenza-virus
#13
Darrell R Kapczynski, Matthew J Sylte, Mary L Killian, Mia K Torchetti, Klaudia Chrzastek, David L Suarez
Between December 2014 and June 2015, North America experienced the largest recorded foreign animal disease outbreak with over 47 million poultry dead or euthanized from viral exposure to a clade 2.3.4.4 H5 highly pathogenic avian influenza (HPAI) epizootic. Soon after the epizootic began, the U.S. Department of Agriculture (USDA) began testing the efficacy of different vaccines as a possible future control strategy. The aim of these studies were to evaluate the efficacy three H5 vaccines to aid in control of HPAI in commercial turkeys...
September 2017: Veterinary Immunology and Immunopathology
https://www.readbyqxmd.com/read/28892353/the-next-wave-of-influenza-drugs
#14
Megan L Shaw
Options for influenza therapy are currently limited to one class of drug, the neuraminidase inhibitors. Amidst concerns about drug resistance, much effort has been placed on the discovery of new drugs with distinct targets and mechanisms of action, with great success. There are now several candidates in late stage development which include small molecules targeting the three subunits of the viral polymerase complex and monoclonal antibodies targeting the hemagglutinin, as well as host-directed therapies. The availability of drugs with diverse mechanisms now opens the door to exploring combination therapies for influenza, and the range of administration routes presents more opportunities for treating hospitalized patients...
September 11, 2017: ACS Infectious Diseases
https://www.readbyqxmd.com/read/28887040/roles-of-antibodies-to-influenza-a-virus-hemagglutinin-neuraminidase-and-m2e-in-conferring-cross-protection
#15
Yu-Jin Kim, Eun-Ju Ko, Min-Chul Kim, Yu-Na Lee, Ki-Hye Kim, Yu-Jin Jung, Sang-Moo Kang
Although neuraminidase (NA) is the second major viral glycoprotein of influenza virus, its immune mechanism as a vaccine target has been less considered. Here we compared the properties of antibodies and the efficacy of cross protection by N1 and N2 NA proteins, inactivated split influenza vaccines (split), and tandem repeat extracellular domain M2 on virus-like particles (M2e5x VLP). Anti-NA immune sera could confer better cross-protection against multiple heterologous influenza viruses correlating with NA inhibition activity compared to split vaccine immune sera...
September 5, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28886946/postmarketing-safety-surveillance-of-trivalent-recombinant-influenza-vaccine-reports-to-the-vaccine-adverse-event-reporting-system
#16
Emily Jane Woo, Pedro L Moro, Maria Cano, Christopher Jankosky
On January 16, 2013, the Food and Drug Administration approved recombinant hemagglutinin influenza vaccine (RIV3) (Spodoptera frugiperda cell line; Flublok), which is the first completely egg-free flu vaccine licensed in the United States. To improve our understanding of the safety profile of this vaccine, we reviewed and summarized reports to the Vaccine Adverse Event Reporting System (VAERS) following RIV3. Through June 30, 2016, VAERS received 88 reports. Allergic reactions, including anaphylaxis, were the most common type of adverse event...
September 5, 2017: Vaccine
https://www.readbyqxmd.com/read/28877235/genetic-and-antigenic-characterization-of-influenza-a-h3n2-in-cameroon-during-the-2014-2016-influenza-seasons
#17
Gwladys C Monamele, Marie-Astrid Vernet, Mohammed R Njankouo, Kathleen Victoir, Jane Francis Akoachere, Damian Anong, Richard Njouom
The first outbreak of influenza A(H3N2) occurred in 1968 and caused the third flu pandemic of the 20th century. It has affected multiple countries over time. The best strategy to reduce the burden of influenza is through vaccination whose efficacy varies with respect to the circulating strains. This study was performed to better understand the molecular evolution of influenza A(H3N2) and assess vaccine efficacy in Cameroon. Complete sequences of three gene segments were obtained from 2014 to 2016 influenza seasons in Cameroon...
2017: PloS One
https://www.readbyqxmd.com/read/28874545/increasing-the-breadth-and-potency-of-response-to-the-seasonal-influenza-virus-vaccine-by-immune-complex-immunization
#18
Jad Maamary, Taia T Wang, Gene S Tan, Peter Palese, Jeffrey V Ravetch
The main barrier to reduction of morbidity caused by influenza is the absence of a vaccine that elicits broad protection against different virus strains. Studies in preclinical models of influenza virus infections have shown that antibodies alone are sufficient to provide broad protection against divergent virus strains in vivo. Here, we address the challenge of identifying an immunogen that can elicit potent, broadly protective, antiinfluenza antibodies by demonstrating that immune complexes composed of sialylated antihemagglutinin antibodies and seasonal inactivated flu vaccine (TIV) can elicit broadly protective antihemagglutinin antibodies...
September 5, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28872136/generation-of-escape-variants-of-neutralizing-influenza-virus-monoclonal-antibodies
#19
Paul E Leon, Teddy John Wohlbold, Wenqian He, Mark J Bailey, Carole J Henry, Patrick C Wilson, Florian Krammer, Gene S Tan
Influenza viruses exhibit a remarkable ability to adapt and evade the host immune response. One way is through antigenic changes that occur on the surface glycoproteins of the virus. The generation of escape variants is a powerful method in elucidating how viruses escape immune detection and in identifying critical residues required for antibody binding. Here, we describe a protocol on how to generate influenza A virus escape variants by utilizing human or murine monoclonal antibodies (mAbs) directed against the viral hemagglutinin (HA)...
August 29, 2017: Journal of Visualized Experiments: JoVE
https://www.readbyqxmd.com/read/28870104/type-ii-transmembrane-serine-proteases-as-potential-target-for-anti-influenza-drug-discovery
#20
Woo-Jin Shin, Baik Lin Seong
The outbreak of an influenza pandemic as well as the continued circulation of seasonal influenza highlights the need for effective antiviral therapies. The emergence of drug-resistant strains further necessitates the development of novel antivirals that target the host factors crucial for viral replication. Area covered: This review summarizes the current understanding of the structural and functional properties of type II transmembrane serine proteases (TTSPs) as a proteolytic activator of influenza virus infection and discusses their potential as antiviral targets...
September 5, 2017: Expert Opinion on Drug Discovery
keyword
keyword
61705
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"